Doubling Down on Immunotherapy in Advanced Melanoma

(MedPage Today) -- Almost 30% of patients with advanced melanoma that progressed on prior checkpoint inhibition responded to pembrolizumab (Keytruda) plus low-dose ipilimumab (Yervoy), according to updated findings from a prospective trial.
Overall...